CURRICULUM VITAE
NAME:
Kelly T. Dineley
DATE: February 8, 2016
PRESENT POSITION AND ADDRESS:
02/10 – Present:
Associate Professor (tenured)
Director, Rodent In Vivo Assessment Core
Primary Appointment: Neurology
Joint Appointments: Neuroscience & Cell Biology
Biochemistry & Molecular Biology
Pharmacology and Toxicology
Mitchell Center for Neurodegenerative Diseases
Center for Addiction Research
Address:
Phone:
FAX:
E-mail:
3.324D Research Building #17
University of Texas Medical Branch
301 University Boulevard
Galveston, Texas 77555-0616
(409) 747-7060
(409) 747-7050
ktdinele@utmb.edu
EDUCATION:
02/98 Ph.D. Neuroscience
06/86 M.S. Cell Biology
06/83 B.A. Biology
Baylor College of Medicine, Houston, TX
University of the Pacific, Stockton, CA
University of the Pacific, Stockton, CA
PROFESSIONAL WORK HISTORY AND TEACHING EXPERIENCE:
02/10 – Present
Associate Professor, Neurology, University of Texas Medical Branch
Galveston, TX
04/03 – 02/10
Assistant Professor, Neurology, University of Texas Medical Branch,
Galveston, TX
01/01 – 04/03
Instructor, Division of Neuroscience, Baylor College of Medicine,
Houston, TX
02/98 – 01/01
Post-doctoral Fellow, Division of Neuroscience, Baylor College of
Medicine, Houston, TX
08/92 – 02/98
Graduate Student, Division of Neuroscience, Baylor College of Medicine,
Houston, TX
09/89 – 08/92
Research Associate, Division of Neuroscience, Baylor College of
Medicine, Houston, TX
02/87 – 07/89
Research Associate, Department of Immunology, Ribi Immunochem, Inc.,
Hamilton, MT
05/86 – 02/87
Research Associate, Connective Tissue Research Labs, Collagen
Corporation, Palo Alto, CA
01/85 – 05/86
Research Associate, Department of Entomology, Shell Agricultural Chemical
Co., Modesto, CA
09/83 – 05/86
Biology Laboratory Instructor, University of the Pacific, Stockton, CA
Kelly T. Dineley, Ph.D.
RESEARCH ACTIVITIES:
 Alzheimer’s disease and Parkinson’s disease and related amyloidopathies, tauopathies,
synucleinopathies.
 Cocaine abuse and addiction.
 Animal models utilizing genetic and pharmacological manipulations.
 Omics approaches to generate novel hypotheses to identify and validate mechanisms that
underlie memory and cognitive deficits induced by aging, neurodegenerative disease, and
drug abuse.
 Nicotinic acetylcholine receptor, nuclear receptor (PPAR), ERK MAPK, CREB, CBP,
protein-protein interactions.
Quantitative Systems Biology in Animal Models
Delivers Unique Insight for Human Disease
Transcriptome Analysis
Proteome Analysis
Response
Elements
MS-MS Zoom Scan – Peptide
Quantification
16
O peptide
Gene Name
Actb
Protein Name
Actin, cytoplasmic 1
Avg.
SEM
9.44
3.46
ADCYAP1R1
Adenylate cyclase activating polypeptide 1
5.53
2.22
Apba2
Amyloid beta A4 precursor protein-binding
8.41
3.50
100
Arpc4
Actin-related protein 2/3 complex subunit 4
3.79
1.33
90
Csnk2a2
Casein kinase II subunit alpha' CK2α
18.07
8.26
Ppp1ca
Ser/thr phosphatase PP1-α catalytic sub
10.65
3.62
Ppp1cc
Ser/thr phosphatase PP1-γ catalytic sub
CMB_SCX_19 #1385
RT: 26.25
NL: 1.52E3
F: ITMS + p NSI d Z m s [ 587.00-599.00]
591.2
18O
95
85
peptide
80
75
9.46
and
3.91
CRE
70
60
Prdx5
Peroxiredoxin-5, mitochondrial
Slc25a5
ADP/ATP translocase 2
7.70
2.40
Snca
α-synuclein
23.68
11.50
35
Snph
Syntaphilin
4.00
0.71
25
Syn1
Synapsin-1
10.69
4.00
Syp
Synaptophysin
5.86
1.78
Apoo
Apolipoprotein O
15.02
5.99
PPRE
Cplx3
complexin 3
4.46
1.51
only
Mapk4
Mitogen-activated protein kinase 4
4.09
1.52
CRE
Pparg
Cbp
PPARγ
8.71
4.32
only
CREB binding protein (CBP)
13.32
5.13
Neither
9.04
593.2
591.7
65
Relative Abundance
25.13
PPRE
55
50
45
593.7
40
592.2
30
592.7
20
594.2
15
594.7
594.6
10
5
0
587
587.8
588.2
588
588.7
589.3
589
590.2
590
595.2
590.7
591
592
593
m /z
594
595.7
595
596.6
596.7
596
597.2
597.6
597
597.7
598
598.2
599
>1,000,000 MS spectra
~40,000 high quality spectra
Network Analysis/Validation
~1,500 proteins
Plasticity
Global
PKA
Fold change > 1.5
and
Statistical significance of p <0.05
~200 proteins
Bioinformatics
Network Validation
Synaptic Structure/Function
Mechanistic Hypotheses
Iterative Models
Mechanistic Hypotheses
Iterative Models
Immune Function
pERK
PPAR
PPAR
Learning
Event
pERK
PPAR
CBP
CRE
PPRE
MEMORY
CONSOLIDATION
Grant Support
1R01AG031859
Dineley (PI)
(NCE)
NIH - National Institute on Aging
07/01/2009–06/30/2014
Kelly T. Dineley, Ph.D.
Mechanisms of PPARγ Enhancement of Cognitive Function in Alzheimer’s
This project will determine the brain region- and cognitive task-specific role of peroxisome
proliferator-activated receptor gamma (PPARγ) underlying the improvement of cognitive function
in an animal model of Alzheimer’s disease by the PPARγ agonist rosiglitazone.
Role: PD/MPI
R01 AG031859-04S1
01/01/2013 – 06/30/2014
NIH Research Supplement to Promote Diversity
Taglialatela (PI)
10/01/2013 – 09/30/2018
1.2 cm
Mechanisms of Resistance to Cognitive Decline in AD
This project will examine factors that provide protection against amyloid toxicity and test a theory
that preserved insulin signaling is a primary mechanism underlying preserved synaptic function.
Role: Co-I
1R01 G042890
Institute for Human Infections and Immunity Stephens (PI)
03/01/2014 – 02/28/2016
Pilot Research Grant in Infections of the CNS
Mechanisms of IL-10 induced cerebral edema and neurological symptoms in P. chabaudi malaria
This project will assess wildtype and IL-10 null mice for susceptibility to neurological complications
following malarial infection
Role: Co-Investigator
Institute for Human Infections and Immunity
Ronca (PI)
Neuro-ID Fellowship
Cognitive Impairment Resulting from Alphavirus Encephalitis
Role: Co-mentor w/Paessler
03/01/2014 – 02/28/2016
Center for Addiction Research
09-2005-present
Cunningham (PI)
1.2 cm
Institutional
In Vivo Assessment Core
Participate in collaborations on addiction research as well as provide career development
mentorship for students, post docs, and new faculty as they pursue addiction-related careers in
pursuit of better treatments for drug addiction.
Role: Director
Jerri and Winki Mohn Foundation Dineley (PI)
01/01/08-12/31/18
Alzheimer’s Disease Therapies
1.2 cm
The goal of this grant is to use unbiased approaches to understand the basic biology of early
cognitive impairment in Alzheimer’s disease.
Role: PI
Completed
A2009063 – American Health Assistance Foundation
06/01/2009 – 05/31/2012
$400,000
PPAR-GAMMA RESCUE OF COGNITIVE FUNCTION IN ALZHEIMER'S DISEASE
Kelly T. Dineley, Ph.D.
Epidemiological studies have shown that Alzheimer's disease (AD) patients often have
hyperinsulinemia. Likewise, patients with insulin resistance associated with type 2 diabetes are
at increased risk for AD. Using a mouse model for AD, we have discovered that the insulinsensitizing drug rosiglitazone (RSG), a potent agonist of peroxisome proliferator-activated
receptor gamma (PPARγ) reverses learning and memory deficits. Therefore, an understanding
of CNS PPARγ regulation, of which virtually nothing is known, will provide new insight into the
pathophysiology and treatment of AD.
Role: PI
RO1AG – NIH
07/01/2009 – 06/30/2011
$650,000
Oligomeric Assemblies Mediate CaN-Dependent Deficits in Cognition
This project will perform a longitudinal study to determine the effectiveness of calcineurin (CaN)
inhibition in ameliorating cognitive deficits induced by oligomeric assemblies of amyloid proteins.
Role: Co-I
Sealy Pilot
10/01/2010 – 09/30/2011
$40,000
PPARγ as a Therapeutic Target in Drug Abuse
Given the important role for learning and memory in the processes through which drug abuse
transitions to addiction, combined with our recent evidence for a role for CNS PPARγ in restoring
cognitive function through effects on ERK MAPK, we hypothesize that that neuronal PPARγ
represents a potential therapeutic target in maintaining abstinence from cocaine self
administration. This pilot study has the potential to validate PPARγ agonist as a new therapeutic
for maintaining abstinence from cocaine use for which there are currently no available
pharmacotherapies.
McManus
11/01/2010 – 10/31/2011
$50,000
PPARγ as a Therapeutic Target in Drug Abuse
Given the important role for learning and memory in the processes through which drug abuse
transitions to addiction, combined with our recent evidence for a role for CNS PPARγ in restoring
cognitive function through effects on ERK MAPK, we hypothesize that that neuronal PPARγ
represents a potential therapeutic target in maintaining abstinence from cocaine self
administration. This pilot study has the potential to validate PPARγ agonist as a new therapeutic
for maintaining abstinence from cocaine use for which there are currently no available
pharmacotherapies.
IIRG-07-59350 – Alzheimer’s Association
09/01/2007 – 08/31/2010
$240,000
Alpha7 nAChR Protects Against Beta-Amyloid Toxicity In Vivo
The goals of this project are to determine the spatial and temporal order of neurodegenerative
changes in a mouse model for AD that also lacks α7 nAChRs.
Role: PI
PPG2007B/6 – Alzheimer’s Research Trust
Glial nAChR Activation by Nicotine and Amyloid.
01.08.2007-31.10.2009
£22325
Kelly T. Dineley, Ph.D.
The goals of this project are to determine whether astrocytic nicotinic receptors are activated by
beta amyloid, with reference to a transgenic Alzheimer’s disease model.
Role: Co PI.
Project: 59884
04/01/08 – 03/31/09
John Sealy Memorial Endowment
$50,000
Mechanisms of PPARγ Enhancement of Cognitive Function in Alzheimer’s
This is a bridging grant while RO1AG031859-02 is pending.
Role: PI
Project: 571201
02/01/2007 – 01/31/09
George and Cynthia Mitchell Center for
Neurodegenerative Disease Research
$70,000
Identification of Therapeutic Targets in Early and Late Alzheimer’s-Related Cognitive Decline
This project investigates the mediators of dysregulated PPARγ in late, severe cognitive decline.
We have used PPARγ agonists to treat the Tg2576 mouse model for AD and found it is a valuable
therapeutic for late stage disease. PPARγ agonism has a plethora of downstream consequences;
therefore discovery of the key mediators of its effectiveness is of importance.
Role: PI
R21-NS053986
07/01/06 – 06/31/08
NIH-NINDS
$137,500
Role of Calcineurin in Aβ-Induced Behavioral Deficits
The major goals of this project are to determine the effective FK-506 treatment regimen for
cognitive benefit in an Alzheimer’s disease mouse model.
Role: Co-I
Project: 59884
07/01/06 – 06/30/08
John Sealy Memorial Endowment
$70,000
Age-Dependent Changes in the NF-kB Signaling Axis in a Mouse Model of AD
The major goals of this project are determine if and which aspects of the NF-kB signaling axis are
dysregulated in an Alzheimer’s disease animal model and what the downstream genetic and
upstream signal transduction consequences of this are.
Role: PI
NIRG-05-13905
Alzheimer’s Association
09/01/05 – 08/31/-07
$100,000
NF-κB Signaling Axis as a Target in Alzheimer’s Disease
The major goals of this project are to test whether an NF-kB inhibitor ameliorates cognitive deficits
in an animal model for AD.
Role: PI
R21 MH072938
07/01/05 – 06/31/07
NIH-NINDS
$135,000
The amygdaloid 5HT-2C receptors in anxiety-like behavior
The major goals of this project are to determine the effect of pharmacological and genetic
manipulation of 5HT-2C receptors on anxiety-like behavior in rodents.
Role: Co-I
Kelly T. Dineley, Ph.D.
17427 – 230 – 148700
09/01/04 – 08/31/06
UTMB Center for Addiction Research
$60,000
Proteome map of nicotine addiction
The major goal of this project is to use mass spectrometry-based proteomics to identify the
molecular mechanisms underlying addictive behavioral alterations induced by nicotine.
Dineley (PI), Denner (Co-PI)
.
Project 13069-04R1
02/01/04 – 01/31/06
John Sealy Memorial Endowment Fund
$70,000
α7 Nicotinic Acetylcholine Receptor as a Mediator of β-Amyloid Toxicity
Role: PI
Texas Tobacco Fund
T.Ashizawa (PI)
Mouse Behavioral Core Facility Development at UTMB
Role: Co-I
9/1/03 – 1/31/04
$200,000
9/1/03 – 8/31/04
$30,000
Influence of Nicotinic Acetylcholine Receptor and β-Amyloid Interaction on Nicotine Addiction
Role: PI
Texas Tobacco Fund
9/1/03 – 8/31/04
$30,000
Correlational Analysis of α7 Nicotinic Acetylcholine Receptor Level on Peripheral Lymphocytes
and Dementia of the Alzheimer’s Type
Role: Co-I
Texas Tobacco Fund
K. McConnell (PI)
NIH-AG05867
9/1/99 – 9/1/02
NRSA
APPswe Effects on Hippocampal Signal Transduction
The goal of the project was to identify signal transduction molecules whose function is deranged
inTg2576 hippocampus
Role: PI
COMMITTEE RESONSIBILITIES:
International
2013-onward Italian Scientists and Scholars of North America Foundation
2012-onward Brain Research United Kingdom Grant Reviewer
National
03-2015
11-2014
07-2014
06-2013
The Paul G. Allen Family Foundation, Allen Distinguished Investigators (ADI)
Program - Life Science Focus
National Institutes of Health Special Emphasis Panel - ZRG1 MDCN-B(05)
National Institutes of Health Special Emphasis Panel P01 Reviews
National Institutes of Health Special Study Section - ZAG1 ZIJ-6 (A1) for RFA
AG-13-013 R01 “Identification and Validation of Novel Targets for AD”
Kelly T. Dineley, Ph.D.
2009-onward National Institutes of Health Ad Hoc Reviewer – Brain Disorders and Clinical
Neuroscience Study Section
06-2011
Veterans Administration Merit Review – Mental Health and Behavioral Sciences
06-2012
Veterans Administration Merit Review – Mental Health and Behavioral Sciences
2012-onward Solix Grant Management solutions Grant Reviewer
State/Regional
2011-2013
Chair, CA Tobacco Related Disease Research Program Study Section
2008-onward CA Tobacco Related Disease Research Program Study Section
2009-onward Arizona Alzheimer's Disease Core Center Ad Hoc Review Program
2011-onward Louisiana Experimental Program to Stimulate Competitive Research
UTMB
1.
Neuroscience Graduate Program, Curriculum and Examination Committees (2003 –
present)
2.
Member University of Texas Graduate School of Biomedical Sciences Faculty (2003present)
3.
Associate Member, Department of Biochemistry and Molecular Biology Faculty (2003 –
present)
4.
Jeane B. Kempner Scholars Review Committee (2003 – 2009)
5.
Judge, National Student Research Forum 45th Annual Meeting, Session D –
Neuroscience, UTMB and AMA Foundation (2004 – 2005)
6.
Fellowship Committee, Member (2004 – present)
7.
Course Development Committee “Neuroscience and Psychopharmacology” for psychiatry
residents, Member (2004)
8.
Member, Center for Addiction, UTMB (2004 – present)
9.
Search Committee, Director of the George and Cynthia Mitchell Alzheimer’s Disease
Research Center (2005)
10.
Member, George and Cynthia Mitchell Alzheimer’s Disease Research Center (2005 –
present)
11.
IACUC Full Board (2006 – present)
12.
IACUC Study Section Subcommittee (2006 – present)
13.
IACUC Infection Control Subcommittee (2006 – 2011)
14.
IACUC Communications User Group (2006 – 2009)
15.
Chair, IACUC Compliance Subcommittee (2009 – present)
16.
Research Advisory Committee (2007 – present)
17.
Animal Resource Center Advisory Committee (2007 – 2009)
18.
Associate Member, Department of Pharmacology and Toxicology Faculty (2007 – present)
19.
Admissions Committee Neuroscience Graduate Program (2009 – 2010)
20.
Neuroscience Graduate Program Internal Review Committee (2010)
21.
Curriculum Committee Chair, Neuroscience Graduate Program (2010 – present)
22.
Center for Addiction Research Endowment Committee (2011 – present)
23.
Neuroscience Graduate Program Advisory Committee (2013 – present)
Departmental
1.
Chair, Research Seminar Series (Mitchell Center for Neurodegenerative Diseases
Seminar Series) (2003 – present)
2.
Chair, Faculty Incentive Plan Committee (2007)
3.
Member, Department Internal Review Committee (2008)
Kelly T. Dineley, Ph.D.
TEACHING RESPONSIBILITIES AT UTMB
School of Medicine
1.
Grand Rounds Presentation, Department of Neurology, one or two lectures per year since
2003.
2.
Clinical Neuroscience, Department of Neurology, two lectures 2005-2006.
3.
Neuroscience and Human Behavior, SOM Yr1: one lecture per academic year, one
facilitation per academic year since 2005-2006.
4.
PBL 2006-2007: one shared (Renal), one full-time (Great Syndromes).
5.
PBL 2009-2010 Neuroscience.
Graduate School
1.
Neurobiology of Disease, one to two lectures per academic year 2010 – present.
2.
Integrative Neuroscience, one to two lectures per academic year 2010 – present.
3.
Course Director for Behavioral Neuroscience, Neuroscience Graduate Program 2008 –
present.
2.
Neural Transmission, one lecture per academic year 2008 – present.
3.
ACC (PHTO 6312), three to five lectures per academic year 2007 – present.
4.
Basic Biology Science Course, Cell Biology, one section per academic year 2007-2008.
5.
Neuroscience and Human Behavior, one section per academic year 2006 – present.
6.
Ethics of Scientific Research, lecture presentation on Ethical Issues in the Use of Animals
for Scientific Research 2008, 2009, 2012, 2013, 2014
7.
Animal Models of Human Disease, one lecture per academic year 2013 – present.
8.
Interview MD/PhD and PhD candidates.
Trainees
Graduate Students
Jennifer Rodriquez-Rivera (2004 – graduated 2011)
Postdoctoral Fellow, Baylor College of Medicine, Dr. Hui Zheng
Honors:
The George Sealy Research Award in Neurology, June 2009
Jordan Jahrling (2009 – graduated 2013)
Postdoctoral Fellow, University of Texas Health Science Center at San Antonio, Dr. Veronica Galvan
Honors:
Leroy Olson, Ph.D. Endowed Scholarship, October 2013
for merit and high academic standards
Jen Chieh and Katherine Huang Scholarship
, October 2013
for research excellence in neuroscience
Fisher Academic Excellence Award in Neuroscience, June 2013
best paper prepared and submitted by a graduate student
Alzheimer’s Association International Conference travel award, July 2012
Peyton and Lydia Schapper Endowed Scholarship, November 2011
outstanding professional and personal leadership among his peers
Ryan Miller (2009 – graduated 2014)
Honors:
Poster Award UTMB Center for Translational Science, February 2013
for excellence in research
Kelly T. Dineley, Ph.D.
CAR
Predoctoral
Fellow
(T32-81758),
September
2011-2013
Streppa Award for Addiction Research, September 2011
for excellence in research
BBC Travel Award Recipient, March 2011
NIEHS Toxicology Predoctoral Fellow (T32-ESO7254), September 2010-2011
Ibdanelo Cortez (2011 – present)
Honors:
R01 AG031859-04S1, January 2013
NIH Research Supplement to parent R01 to Promote Diversity
Shannon Ronca (2014 – present)
Experimental Pathology, Ph.D.; co-mentored with Dr. Slobodon Paessler
Honors:
IHII Neuro-ID Fellowship, March 2014
Andrea Dimet (2014 – present)
Medical Students
Travis Urban (2014 – present)
Honors:
American Academy of Neurology Medical Student Summer Research
Scholarship, June 2014
Medical Student Summer Research Program (MSSRP), May 2014
Medical Student Training in Aging Research (MSTAR), May 2014
Alzheimer’s Association International Conference Travel Award, May 2014
Postdoctoral Fellows
Caterina Hernandez (2007 – 2012) Scientist, Medical College Georgia
Narayana Komaravelli (2010 – 2011), Postdoctoral Fellow, UTMB Galveston
Miroslav Nenov (2011 – 2013), Postdoctoral Fellow, Pharmacology & Toxicology
Graduate Student Advisees
1.
Natalie Robeson, Pharmacology & Toxicology Graduate Program, M.S.
Graduated 2006
2.
Krystyn Bourne, Biochemistry Graduate Program, Ph.D.
Graduated 2005
3.
Diana Ferrari, Neuroscience Graduate Program, Ph.D.
Graduated 2009
4.
Bridget Hawkins, Neuroscience Graduate Program, UTMB, Ph.D.
Graduated 2008
5.
Noelle Anastasio, Pharmacology and Toxicology Graduate Program, Ph.D.
Graduated 2009
6.
Yan Xia, Pharmacology and Toxicology Graduate Program, Ph.D.
Graduated 2009
7.
Cristian Lasagna, Neuroscience Graduate Program, Ph.D.
Graduated 2011
8.
Lindsey Reese, Neuroscience Graduate Program, Ph.D.
Graduated 2011
9.
Zane Martin, Neuroscience Graduate Program, Ph.D.
Graduated 2012
Kelly T. Dineley, Ph.D.
10.
11.
12.
13.
14.
15.
Mathieu Bakhoum, Neuroscience Graduate Program, Ph.D., M.D.
Graduated 2012
Alex Martinez, University of Texas Health Science Center at San Antonio
Graduated 2014
Tanzeen Yousef, Neuroscience Graduate Program, Ph.D.
Graduated 2014
Shannon Ronca, Microbiology and Immunology, Institute for Human Infections and
Immunity
David McCue, Pharmacology and Toxicology
Yafang Zhang, Pharmacology and Toxicology
MEMBERSHIP IN SCIENTIFIC SOCIETIES
1995 – present
Society for Neuroscience
1995 – present
American Association for the Advancement of Science
2011 – present
New York Academy of Sciences
2013 – present
International Society to Advance Alzheimer’s Research and Treatment
HONORS
1993 Graduate Student Council Representative Baylor College of Medicine
1995 National Research Service Award, pre-doctoral
5 years
2000 National Research Service Award, post-doctoral
3 years
2002 National Institute of Aging Travel Award
2002 New York Academy of Sciences Travel Award
2005 Travel Fellowship, Winter Conference on Brain Research, Breckenridge, CO
2012 Invited Member, Center for Houston’s Future: The Regions Think Tank
RESEARCH HIGHLIGHTS IN THE PRESS
2003 Alzheimer Research Forum News New Orleans: Kelly Dineley Reports from Satellite
Social
http://www.alzforum.org/new/detail.asp?id=920
2007
Dineley KT, Hogan D, Zhang WR, Taglialatela G. Acute inhibition of calcineurin restores
associative learning and memory in Tg2576 APP transgenic mice. Neurobiol Learn Mem.
2007 Sep;88(2):217-24. PubMed Abstract
http://www.alzforum.org/pap/annotation.asp?powID=66587
2010
Alzheimer Research Forum Papers of the Week: Hernandez CM, Kayed R, Zheng H,
Sweatt JD, Dineley KT. “Loss of alpha7 nicotinic receptors enhances beta-amyloid
oligomer
accumulation,
exacerbating
early-stage
cognitive
decline
and
septohippocampal pathology in a mouse model of Alzheimer's disease”. J Neurosci.
2010 Feb 17;30(7):2442-53. PubMed Abstract
http://www.alzforum.org/pap/annotation.asp?powID=99529
2010
Alzheimer Research Forum News: Aβ and α7: Sordid Affair Begins With Healthy
Partnership?
http://www.alzforum.org/new/detail.asp?id=2372
2012
Alzheimer Research Forum Papers of the Week: Denner LA, Rodriguez-Rivera J,
Haidacher SJ, Jahrling JB, Carmical JR, Hernandez CM, Zhao Y, Sadygov RG, Starkey
Spratt H, Luxon BA, Wood TG, Dineley KT. “Cognitive enhancement with rosiglitazone
JM,
Kelly T. Dineley, Ph.D.
links the hippocampal PPARγ and ERK MAPK signaling pathways”. J Neurosci. 2012 Nov
21;32(47):16725-35a. PubMed Abstract
http://www.alzforum.org/pap/annotation.asp?powID=139955
2012
University of Texas Medical Branch at Galveston Press Release:
http://www.utmb.edu/newsroom/article8071.aspx
2012
Alzheimer Research Forum News:
http://www.alzforum.org/new/detail.asp?id=3337
2012
American Health Assistance Foundation News:
http://www.ahaf.org/alzheimers/newsupdates/ahaf-funded-research-shows.html
2012
Guidry News: “A Visit with Drs. Larry Denner
http://www.guidrynews.com/story.aspx?id=1000047618
2012
Inclusion of “PPARγ Drug Abuse Therapeutic” Project in Patient Impact Initiative
(Partnership for Cures) http://www.cureswithinreach.org/15-research/researchprojects/87-ppargamma-as-a-therapeutic-target-in-drug-abuse
2012
Invited commentary: “Diabetes: Funding, education and awareness”, Galveston Daily
News, Nov. 13, 2012
2013
UTMB Fisher Academic Excellence Award in Neuroscience - Cognitive Enhancement
following PPARy Agonism is Mediated by a Hippocampal pERK-PPARy Complex During
Memory Consolidation in Alzheimer’s Disease
and
Kelly
Dineley”
UTMB OFFICE FOR UNIVERSITY ADVANCEMENT OUTREACH ACTIVITIES
2008 Keynote Speaker, Mohn Salon: “An evening with President David L. Callender and Mrs.
Teri Wenglein- Callender”.
2013 Fort Worth Regional Leadership Council for Working Wonders – The Campaign
for UTMB Health
2014 Keynote Speaker, UT Chancellor’s Council Executive Committee Winter Meeting
2014 Hosted UTMB OUA site visit for Mr. Ferald Belote
2014 Hosted UTMB OUA site visit for The Nakfoor Family
ADDITIONAL INFORMATION:
Community Outreach:
2010
Keynote Speaker, Galveston Aging Care Network
2012
Alzheimer’s Disease Research Update: Seaside Senior Expo, Moody Methodist
Church, Galveston, TX
2013
Keynote Speaker, Alzheimer’s Disease Research Update: Seaside Senior Expo,
Moody Methodist Church, Galveston, TX
2013
Alzheimer’s Disease Research Update: Aging Professionals Networking
Breakfast, Galveston Island Community Center, Galveston, TX
2014
Keynote Speaker, Weslaco Knapp Medical Center Conference on Alzheimer’s
Disease, Harlingen, TX
2015
Judge, Science and Engineering Fair of Galveston County, Galveston College,
Texas A&M University, University of Texas Medical Branch
Journal Reviews
Journal of Neuroscience
Journal of Neurochemistry
Kelly T. Dineley, Ph.D.
Neurobiology of Disease
Journal of Neuropharmacology
Brain Research
Behavioral Brain Research
Aging Cell
Neurobiology of Learning and Memory
Neurobiology of Aging
Journal of Neurophysiology
Drug and Alcohol Dependence
Neuropsychopharmacology
Biological Psychiatry
Molecular and Cellular Biochemistry
PloS ONE
Hippocampus
Journal of Physiology
Grant Reviews
Alzheimer’s Association
Arizona's Institute for Mental Health Research
California’s Tobacco-Related Disease Research Program - Chair
James and Esther King Biomedical Research Program
Louisiana State Pilot Research Program
National Institutes of Health Special Emphasis Panels
NIH Ad Hoc Reviewer for BDCN Study Section
Paul G. Allen Family Foundation
United Kingdom Brain Research Foundation
Veterans Administration ad hoc reviewer
Patent Information:
11/2001
Invention disclosure entitled “Rat-Mouse Chimeric Receptor cDNA That Allows
Significant Surface Expression of α-7 nAChR Extracellular Domain on the Surface of
Cells. Case number 02-053.
01/2015
Invention disclosure: B6-Chrna7LBDEx4007Ehs mice in which the Chrna7 gene (exon
4) was flanked by loxP sites to create mice in which α7 nAChRs can be deleted
in a conditional manner.
PUBLISHED:
A.
ARTICLES IN PEER-REVIEWED JOURNALS:
1. Dineley KT, Pandya AA, Yakel JL. Nicotinic ACh receptors as therapeutic targets in CNS
disorders. Trends Pharmacol Sci. 2015 Jan 29. pii:S0165-6147(14)00215-6. doi:
10.1016/j.tips.2014.12.002. Review. PubMed PMID: 25639674.
2. Dineley KT, Jahrling JB, Denner L. Insulin resistance in Alzheimer's disease. Neurobiol
Dis. 2014 Dec;72 Pt A:92-103. doi: 10.1016/j.nbd.2014.09.001. Epub 2014 Sep 16.
PubMed PMID: 25237037; PMCID: PMC4253975.
3. Nenov MN, Tempia F, Denner L, Dineley KT, Laezza F (2014) Impaired firing properties
of dentate granule neurons in an Alzheimer's disease animal model are rescued by
PPARγ agonism. J Neurophys Dec 24:jn.00419.2014. doi: 10.1152/jn.00419.2014.
4. Fawver JN, Ghiwot Y, Koola C, Carrera W, Rodriguez-Rivera J, Hernandez C, Dineley
KT, Li J, Jhamandas J, Perry G, and Murray IVJ (2014) Islet Amyloid Polypeptide (IAPP)
Kelly T. Dineley, Ph.D.
5.
6.
7.
8.
Association with Alzheimer’s Disease Pathology and Diagnosis. Current Alzheimer’s
Res, Curr Alzheimer Res. 2014;11(10):928-40. PMID:25387341
Hernandez CM, Cortez I, Gu Z, Colón-Sáez JO, Lamb PW, Wakamiya M, Yakel JL,
Dineley KT (2014) Research tool: validation of floxed α7 nicotinic acetylcholine receptor
conditional knockout mice using in vitro and in vivo approaches. J Physiol. Aug 1;592(Pt
15):3201-14. doi: 10.1113/jphysiol.2014.272054. PMID: 24879866; PMCID:
PMC4146370.
Jahrling JB, Hernandez CM, Denner L, Dineley KT (2014) PPARγ recruitment to active
ERK during memory consolidation is required for Alzheimer’s disease-related cognitive
enhancement. J Neurosci. Mar 12;34(11):4054-63. doi: 10.1523/JNEUROSCI.402413.2014. PMID: 24623782
Castillo-Carranza, DL, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Gerson
JA, Singh G, Estes DM, Barrett ADT, Dineley KT, Jackson GR, Kayed R (2014) Passive
Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes
without Affecting Hyperphosphorylated Neurofibrillary Tangles. J Neurosci
19;34(12):4260-72. doi: 10.1523/JNEUROSCI.3192-13.2014. PMID: 24647946
Nenov MN, Laezza F, Haidacher SJ, Zhao Y, Sadygov RG, Starkey JM, Spratt H, Luxon
BA, Dineley KT, Denner L. (2013) Cognitive enhancing treatment with a PPARγ agonist
normalizes dentate granule cell presynaptic function in Tg2576 APP mice. J Neurosci
34(3):1028-36. doi: 10.1523/JNEUROSCI.3413-13.2014
9. Pirttimaki T, Codadu NK, Awni A, Pratik P, Nagel D, Hill EJ, Dineley KT, Parri HR (2013)
α7 nicotinic receptor-mediated astrocytic gliotransmitter release: Aβ effects in a preclinical
Alzheimer’s mouse model. PLoS ONE November 28;8(11):e81828.
doi:
10.1371/journal.pone.0081828.
10. Cook NP, Archer CM, Fawver JN, Schall HE, Rodriguez-Rivera J, Dineley KT, Martí AA,
Murray IV (2013) Ruthenium red colorimetric and birefringent staining of amyloid-β
aggregates in vitro and in Tg2576 mice. ACS Chem Neurosci. 20;4(3):379-84. doi:
10.1021/cn300219n.
11. Yan J, Mei FC, Cheng H, Lao DH, Hu Y, Wei J, Patrikeev I, Hao D, Stutz SJ, Dineley KT,
Motamedi M, Hommel JD, Cunningham KA, Chen J, Cheng X (2013) Enhanced leptin
sensitivity, reduced adiposity, and improved glucose homeostasis in mice lacking
exchange protein directly activated by cyclic AMP isoform 1. Mol Cell Biol. 2013
Mar;33(5):918-26. doi: 10.1128/MCB.01227-12.
12. Denner LA, Rodriguez-Rivera J, Haidacher SJ, Jahrling JB, Carmical JR, Hernandez CM,
Zhao Y, Sadygov RG, Starkey JM, Spratt H, Luxon BA, Wood TG, Dineley KT (2012)
Cognitive Enhancement with Rosiglitazone Links the Hippocampal PPARγ and ERK
MAPK Signaling Pathways. J Neurosci 32(47):16725-35. PMID: 23175826
13. Martin ZS, Neugebauer V, Dineley KT, Kayed R, Zhang W, Reese LC, Taglialatela G.
(2012) α-Synuclein oligomers oppose long-term potentiation and impair memory through
a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. J
Neurochem. 120(3):440-52. PMID: 22060133
14. Parri HR, Hernandez CM, Dineley KT (2011) Research update: Alpha7 nicotinic
acetylcholine receptor mechanisms in Alzheimer's disease. Biochem Pharmacol.
82(8):931-42. PMID: 21763291
15. Rodriguez-Rivera J., Denner, L.A., Dineley K.T. (2011) Rosiglitazone reversal of cognitive
deficits in Tg2576 is independent of peripheral gluco-regulatory status. Behav. Brain Res.
216(1):255-61. PMID: 20709114
Kelly T. Dineley, Ph.D.
16. Dineley KT, Kayed R, Neugebauer V, Fu Y, Zhang W, Reese LC, Taglialatela G (2010)
Amyloid-beta oligomers impair fear conditioned memory in a calcineurin-dependent
fashion in mice. J Neurosci Res. 88(13):2923-32.
17. Hernandez CM, Kayed R, Zheng H, Sweatt JD and Dineley KT (2010) Loss of α7 nicotinic
receptors enhances Aβ oligomer accumulation exacerbating early-stage cognitive decline
and septo-hippocampal pathology in a mouse model for Alzheimer’s disease. J Neurosci.
30(7):2442–2453.
18. Taglialatella G, Hogan D, Zhang W-R and Dineley KT (2009) Intermediate- and long-term
recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition.
Behav Brain Res. 200(1):95-9.
19. Resse, L.C., Zhang, W., Dineley, K.T., Kayed, R., Taglialatela, G. (2008) Selective
induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell.
7(6):824-35.
20. Cole, A.R., Noble, W., van Aalten, L., Yoshida, H., Plattner, F., Meimaridou, R., Hogan,
D., LaFrancois, J., Taylor, M., Gunn-Moore, F., Verkhratsky, A., Oddo, S., La Ferla, F.,
Duff, K., Goedert, M., Giese, K.P., Dineley, K.T., Richardson, J.C., Hanger, D.P., Allan,
S.M., Sutherland, C. (2007) Collapsin response mediator protein-2 hyperphosphorylation
is an early event in Alzheimer’s disease progression. J. Neurochem. 103(3):1132-44,
2007 Nov.
21. Dineley, K.T., Hogan, D., Ru, W., Taglialatela, G. (2007) Acute inhibition of calcineurin
restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol.
Learn. Mem. 88(2):217-24, 2007 Sep.
22. Jones IW, Westmacott A, Chan E, Jones RW, Dineley K, O'Neill MJ, Wonnacott S. (2006)
Alpha7 nicotinic acetylcholine receptor expression in Alzheimer's disease: receptor
densities in brain regions of the APP(SWE) mouse model and in human peripheral blood
lymphocytes. J Mol Neurosci. 30(1-2):83-84.
23. Hotte M., Thuault S., Dineley K.T., Hemmings H.C., Nairn A.C., Jay T.M. (2006)
Phosphorylation of CREB and DARPP-32 during late LTP at hippocampal to prefrontal
cortex synapses in vivo. Synapse. 61(1):24-28.
24. Hotte M., Thuault, S.J., Lachaise F., Dineley K.T., Hemmings H.C., Nairn A.C., Jay T.M.
(2006) D1 receptor modulation of memory retrieval performance is associated with
changes in pCREB and pDARPP-32 in rat prefrontal cortex. Behavioral Brain Research.
171:127-133.
25. Bell, K.A., O’Riordan, K.J., Sweatt, J.D. and Dineley, K.T. (2004) MAPK recruitment by amyloid in organotypic hippocampal slice cultures depends on physical state and
exposure time. J. Neurochem. 91:349-361.
26. Wang, R., Dineley, K.T., Sweatt, J.D. and Zheng, H. (2004) Presenilin 1 familial
Alzheimer’s disease mutation leads to defective association learning and impaired adult
neurogenesis. Neurosci. 126:305-312
27. Galvan, C.D., Wenzel, J.H., Dineley, K.T., Lam, T.T., Schwartzkroin, P.A., Sweatt, J.D.
and Swann, J.W.
(2003) Postsynaptic contributions to hippocampal network
hyperexcitability induced by chronic activity blockade in vivo. Eur. J. Neurosci. 18:18611872.
Kelly T. Dineley, Ph.D.
28. Dineley K.T., Bell K.A., Bui D., and Sweatt J.D. (2002) β-amyloid peptide activates α7
nicotinic acetylcholine receptors expressed in Xenopus oocytes. J. Biol. Chem.
277:25056-25061.
29. Dineley K.T., Xia X., Bui D., Sweatt J.D. and Zheng H. (2002) Accelerated plaque
accumulation, associative learning deficits and up-regulation of α7 nicotinic acetylcholine
receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid
precursor proteins. J. Biol. Chem. 277:22768-22780.
30. Adams J.P., Anderson A.E., Varga A.W., Dineley K.T., Cook R.G., Pfaffinger P.J., and
Sweatt J.D. The A-type potassium channel, Kv4.2, is a substrate for the mitogen activated
protein kinase, ERK. J. NeuroChem. 75:2277-2287; 2000.
31. Dineley K.T., Westerman M., Bui D., Bell K., Hsiao Ashe K. and Sweatt J.D. (2001) Betaamyloid activates the mitogen-activated protein kinase cascade through hippocampal α7
nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer’s
disease. J. Neurosci. 21:4125-4133.
32. Dineley K.T. and Patrick J. (2000) Molecular determinants of alpha7 nAChR surface
expression. J. Biol. Chem. 275:13974-13985.
33. Goldner F., Dineley K.T., and Patrick J. (1997) Immunohistochemical localization of the
nicotinic acetylcholine receptor subunit alpha6 to dopaminergic neurons in the substantia
nigra and ventral tegmental area. Neuroreport 8:2739-2742.
34. Neff S., Dineley-Miller K.T., Char D., Quik M., and Patrick J. (1995) Production of
polyclonal antisera that recognize and distinguish between the extracellular domains of
neuronal nicotinic acetylcholine receptor subunits. J. Neurochem. 64:332-339.
35. Seguela P., Wadiche J., Dineley-Miller K.T., Dani J., and Patrick J. (1993) Molecular
cloning, functional properties, and distribution of rat brain alpha7: a nicotinic cation
channel highly permeable to calcium. J. Neurosci. 13:596-604.
36. Dineley-Miller K.T., and Patrick J. (1992) Gene transcripts for the nicotinic acetylcholine
receptor subunit, beta4, are distributed in multiple areas of the rat central nervous system.
Mol. Brain Res. 16:339-344.
37. McPherson J.M., Sawamura S.J., Ogawa Y., Dineley K.T., Carrillo P. and Piez K.A. (1989)
The growth inhibitor of African green monkey (BSC-1) cells is transforming growth factors
beta 1 and beta 2. Biochemistry. 28(8): 3442-3447.
B.
OTHER
Reviews
1.
Dineley KT, Pandya AA, Yakel JL (2014) Nicotinic ACh Receptors as Therapeutic
Targets in CNS Disorders. Trends in Pharm Sciences in press.
2.
Dineley KT, Jahrling JB, Denner L (2014) Insulin Resistance in Alzheimer’s Disease.
Neurobiol of Disease. 72PA:92-103
PMID:25237037
Kelly T. Dineley, Ph.D.
3.
Hernandez CM, Dineley KT (2012) α7 nicotinic acetylcholine receptors in Alzheimer’s
disease: neuroprotective, neurotrophic, or both? Curr Drug Targets. 13(5):613-22. PMID:
22300028
4.
Parri HR and Dineley KT (2009) Nicotinic receptor – beta-amyloid interaction: molecular,
cellular, and physiological consequences. Curr Alz Res 82(8):931-42
5.
6.
7.
PMID: 21763291
Dineley, K.T. Aβ peptide and nicotinic acetylcholine receptor interaction: The two faces
of health and disease. (2007) Frontiers in Bioscience: Nicotinic Acetylcholine Receptors
in Adult and Developing Brain. 12: 5030-5038.
Dineley, K.T., Weeber, E.J., Atkins, C.M., Adams, J.P., Anderson, A. and Sweatt, J.D.
(2001) Leitmotifs in the biochemistry of LTP induction: amplification, integration, and
coordination. J. Neurochem. 77:961-971.
Patrick J.W., Neff S., Dineley K., Char D. (1996) Immunological approaches to nicotine
receptors. NIDA Res. Mono. 161:3-19.
Book Chapters
1.
Dineley, K.T. Nicotinic Acetylcholine Receptors in Neurodegenerative Disease. 2013
Springer.
INVITED LECTURES AT SYMPOSIA AND CONFERENCES:
2000-2002
Presenter, “NeuroReports” Divisison of Neuroscience, Baylor College of
Medicine, Houston, TX
2000
Invited speaker, University of Minnesota, Minneapolis, MN
2001
Invited speaker, R.W. Johnson Pharmaceutical Research Inst., Springhouse, PA
2002
Invited speaker, AstraZeneca, Wilmington, DE
2002
Invited speaker, Huffington Center on Aging, Baylor COM, Houston, TX
2003
Invited speaker, Dept. of Neurology, Univ. of Texas Med. Br., Galveston, TX
2003
Invited speaker, Gladstone Inst. of Neurological Disease, U of CA, San Francisco
2003
Presenter, Program in Neuroscience Seminar Series, UTMB, Galveston, TX
2004-present Presenter, Mitchell Center for Neurodegenerative Diseases Seminar, UTMB,
Galveston, TX
2004-present Presenter, Neurology Grand Rounds, UTMB, Galveston, TX
2004
Invited speaker, Society for Neuroscience, 34th Annual Meeting, San Diego, CA
2005
Invited speaker, Winter Conference on Brain Research, Breckenridge, CO
2005
Invited speaker, Society for Neuroscience, 35th Annual Meeting, Washington, DC
2005
Invited speaker, 8th Annual Schlichting Education Conference, sponsored by the
Houston Alzheimer’s Association and the Houston Area Agency on Aging.
2005
Invited speaker, Texas – UK Biomedical Research Coalition, University of Dundee,
Dundee, Scotland, UK
2005-present Presenter, Center for Addiction Research, UTMB, Galveston
2008
Invited speaker, Aston University, Birmingham, England, UK
2008
Invited speaker, University of Bath, Bath, England, UK
2008
Invited speaker, Nicotinic Acetylcholine Receptors Wellcome Trust 2008 Meeting,
Cambridge, England, UK
2008
Invited speaker, Texas Southwest Chapter of the Alzheimer’s Association,
Houston, TX
2008
Invited speaker, The Mind and Criminal Defense, Center for American and
International Law, Dallas, TX
Kelly T. Dineley, Ph.D.
2009
2010
2010
2011
2011
2012
2013
2013
2015
Invited speaker, Barrow Neurological Institute, Phoenix, AZ
Invited speaker: Texas A&M, College Station, TX
Invited speaker, The Mind and Criminal Defense, The Center for American and
International Law, Dallas, TX
Invited speaker, Nicotinic Acetylcholine Receptors Wellcome Trust 2011 Meeting,
Cambridge, England, UK
Invited speaker, Aston University, Birmingham, England, UK
Invited speaker, Tulane University, New Orleans, LA
Invited speaker, Keystone Symposia “New Frontiers in Neurodegenerative
Disease Research”, Santa Fe, NM
Invited speaker, Alzheimer’s Association 7th Annual Research Symposium,
Houston, TX
Invited speaker, Winter Conference on Neural Plasticity, Barbados, Caribbean